PDGene


	The Michael J. Fox Foundation for Parkinson's Research

		Research
		News & Events
		Funding Programs
		About

	PD Online Research

	Alzheimer Research Forum

		Current Papers
		ARF Recommends
		Research News

Gene overview of all published PD-association studies for ABCB1

Gene:

ABCB1 (CLCS; MDR1; P-gp; PGY1; ABC20; CD243; GP170)

View on AlzGene View on MSGene View on SZGene

Protein:

ATP-binding cassette sub-family B member 1 (P glycoprotein 1; colchicin sensitivity; doxorubicin resistance; multidrug resistance 1)

Chromosome:

7 (View: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 X Y MT)

Status:

Updated 25 July 2010

1. Case-Control Studies (by ethnic group)
				PD Cases				Normal Controls
Study	Population	Source	# Polys	# Subjects (% women)	DX	Onset Age (range)	Age (range)	# Subjects (% women)	Age (range)	Result	Comment
Caucasian
Drozdzik, 2003	Poland	CL	1 (detail)	107 (48%)	C	-	57.2 + 11.4 (24-82)	103 (51%)	74.1 + 5.9 (65-93)	Positive	Submit comment
Dutheil, 2010	France	CL	2 (detail)	207 (43%)	-	65 (-)	69 (-)	482 (41%)	69 (-)	Positive
Fung, 2006	Overlaps with Simon-Sanchez, 2009 (USA)	CL	3 (detail)	267 (-)	C	-	-	270 (-)	68 (55-88)	Negative	Submit comment
Funke, 2009	Germany	CL	4 (detail)	300 (36%)	C	56.2 + 11 (30-86)	66.4 + 10.3 (39-90)	302 (34%)	60.6 + 5.2 (53-84)	Negative	Submit comment
Furuno, 2002	Italy	CL	3 (detail)	95 (37%)	C	52.9 (-)	61.1 (31-84)	106 (47%)	52.4 + 14.7 (-)	Positive	Submit comment
Pankratz, 2008	USA (PROGENI, GenePD)	CL	1 (detail)	857 (41%)	C	61.9 + 10.8 (-)	-	867 (60%)	54.8 + 13.1 (-)	Negative	Submit comment
Simon-Sanchez, 2009	USA, Germany (GWAS)	CL,PO	1 (detail)	1745 (45%)	C	55.8 (7-98)	-	4047 (50%)	-	Negative
Tan, 2004	Poland	CL	7 (detail)	158 (43%)	C	-	63.3 + 9.1 (42-88)	139 (50%)	73.1 + 5.9 (55-90)	Trend	Submit comment
Westerlund, 2009	Sweden	CL	3 (detail)	288 (39%)	C	59.9 (-)	67.8 (24-90)	313 (56%)	57.9 (20-89)	Positive	Submit comment
Zschiedrich, 2009	Germany	CL	3 (detail)	265 (40%)	C	45 + 13.7 (-)	55.1 + 13.4 (-)	123 (49%)	51 + 12.4 (-)	Positive	Submit comment
Zschiedrich, 2009	Serbia	CL	3 (detail)	42 (40%)	C	43.3 + 5.9 (-)	53.5 + 6.3 (-)	61 (69%)	50.7 + 14.4 (-)	Positive	Submit comment
Asian
Lee, 2004	Singapore	CL	7 (detail)	206 (47%)	C	60.5 + 10.7 (32-85)	66.3 + 9.6 (40-92)	224 (47%)	65.4 + 9.4 (39-93)	Positive	Submit comment
Mizuta, 2006	Overlaps with Mizuta, 2008	CL	4 (detail)	882 (56%)	C	57.4 + 10.9 (-)	64.9 + 9.8 (-)	938 (48%)	45.3 + 16.3 (-)	Negative	Submit comment
Mizuta, 2008	Japan	CL	1 (detail)	882 (56%)	C	57.4 + 10.9 (-)	64.9 + 9.8 (-)	938 (48%)	45.6 + 16.3 (-)	Negative	Submit comment
Momose, 2002	Overlaps with Mizuta, 2008	CL	1 (detail)	232 (51%)	C	54.1 + 10.5 (24-80)	-	249 (49%)	-	n.a.	Submit comment
Tan, 2005	China	CL	7 (detail)	185 (47%)	C	-	68.9 + 10.9 (24-96)	206 (50%)	70.3 + 10.5 (30-94)	Positive	Submit comment
Toda, 2003	Overlaps with Mizuta, 2008	CL	1 (detail)	232 (51%)	C	54.1 + 10.5 (24-80)	-	249 (49%)	-	n.a.	Submit comment

Contact us if you are an author of an association study regarding this gene and do not find your study in this table or find errors in the representation of your study details.

Source:  Source of case population -> “CL” (clinic-based), “PO” (population-based), or “CO” (community-based).
# Polys:  Number of polymorphisms tested per gene and per sample.
Onset Age and Age:  Mean or median age at onset or examination, respectively.
DX:  Criteria used to determine PD diagnosis -> "C" (clinical PD diagnosis), "N" (neuropathological PD diagnosis), "M" (mixed, i.e. PD sample contains both clinical and neuropathological cases), "U" (unknown).
Result:  Overall conclusion reached by authors of the original publication (“positive” usually indicates significant (P<0.05) association in at least one of the performed analyses, and “negative” indicates no evidence for significant association, while “trend” indicates results in between).
(-) :  Either no data provided or in case of overlap, data included in original study.